

1/8

FIG. 1A




FIG. 1B





FIG. 1C



BEST AVAILABLE COPY

FIG. 2A




FIG. 2B






FIG. 2C





| TSU-Pr (human prostate) tumor | #1 | #2 | #3 | #4 | #5 | #6 |
|---|--------|--------|-------|-------|--------|-------|
| Initial tumor implant weight (mg) | 53.00 | 52.00 | 53.00 | 54.00 | 54.00 | 53.00 |
| After 7 days, control tumor weight (mg) | 69.90 | 66.10 | 62.50 | 75.00 | 92.70 | 72.90 |
| After 7 days: Initial wt = Total Increase in Control | 16.70 | 12.90 | 9.30 | 21.80 | 39.50 | 19.70 |
| Tumors with acetyl-SNS-carboxamide | | | | | | |
| 45 μ g acetyl-acetyl-SNS-carboxamide | 48.00 | 44.70 | 53.50 | 56.80 | 49.70 | 58.20 |
| After 7 days: Inhibitor weight - Initial Implant weight | -5.20 | -8.50 | 0.30 | 3.60 | -3.50 | 5.00 |
| % of Total weight | -28.06 | -45.87 | 1.62 | 19.43 | -18.89 | 26.98 |
| % Inhibition of tumor wt by acetyl-SNS-carboxamide | 128.06 | 145.87 | 98.38 | 80.57 | 118.89 | 73.02 |

FIG. 3A



| TSU-Pr (human prostate) tumor | #7 | #8 | #9 | #10 | MEAN | STD | SEM |
|---|--------|--------|--------|-------|---------------|-------|------|
| Initial tumor implant weight (mg) | 54.00 | 54.00 | 52.00 | 53.00 | <u>53.20</u> | 0.79 | 0.35 |
| After 7 days: control tumor weight (mg) | 72.50 | 67.40 | 78.00 | 67.40 | 72.44 | 8.46 | 2.99 |
| After 7 days: Initial wt = Total Increase in Control | 15.90 | 15.90 | 16.70 | 16.90 | <u>18.53</u> | 8.11 | 2.56 |
| Tumors with acetyl-SNS-carboxamide | | | | | | | |
| 45 μ g acetyl-SNS-carboxamide | 48.60 | 47.40 | 46.80 | 58.40 | | | |
| After 7 days: Inhibitor weight - Initial Implant weight | -4.60 | -5.80 | -6.40 | 5.20 | <u>51.21</u> | 5.09 | 1.61 |
| % of Total weight | -24.82 | -31.30 | -34.54 | 28.06 | | | |
| % Inhibition of tumor wt by acetyl-SNS-carboxamide | 124.82 | 131.30 | 134.54 | 71.94 | <u>110.74</u> | 27.45 | 8.68 |

FIG. 3B



| SNS Tag ID | Tube Length (mm) 5 μ g/mL/well | % Inhibition | SEM | Angiogenesis Index 15 μ g/CAM | % Inhibition |
|--------------------------|---------------------------------------|-----------------|--------|---|-----------------|
| EBM Control | 0.7206 +/- 0.03 | | | 51 +/- 9.7 | |
| Growth Factor Control | 1.7886 +/- 0.09 | | | 162.22 +/- 15.3 | |
| S_A_S | 1.4564 +/- 0.14 | 31.103 | 15.053 | | |
| S_0_S | 1.0423 +/- 0.12 | 69.879 | 18.343 | 70.66 +/- 7.4 | 82.31 +/- 6.6 |
| s_n_S | 1.5152 +/- 0.06 | 25.597 | 8.8465 | | |
| s_n_S | 1.8351 +/- 0.07 | -4.3596 | 6.688 | | |
| S_G_S | 1.3653 +/- 0.08 | 39.632 | 11.725 | | |
| S_E_S | 1.9891 +/- 0.08 | -18.776 | 11.056 | | |
| s_N_S | 1.3186 +/- 0.09 | 44.008 | 9.718 | | |
| s_n_S | 1.9624 +/- 0.15 | -16.273 | 23.402 | | |
| S_D_S | 1.9624 +/- 0.15 | 32.935 | 14.458 | | |

Continued on Fig. 4B

FIG. 4A



Continued from Fig. 4A

| SNS Tag ID | Tube Length (mm) 5 μ g/mL/well | % Inhibition | SEM | Angiogenesis Index 15 μ g/CAM | % Inhibition |
|---------------|---------------------------------------|-----------------|--------|---|-----------------|
| S_n_s | 1.6803 +/- 0.06 | 10.141 | 6.3189 | | |
| S_N_s | 1.2702 +/- 0.22 | 48.54 | 34.054 | 85.55 +/- 9.1 | 68.93 +/- 8.19 |
| S_n_s | 1.3933 +/- 0.06 | 37.014 | 9.3608 | | |
| +4Hyp_N_S | 1.3244 +/- 0.08 | 43.462 | 9.173 | | |
| +4Hyp_N_+4Hyp | 1.9347 +/- 0.18 | -13.679 | 28.834 | | |
| S_N_+4Hyp | 0.6404 +/- 0.07 | 107.51 | 11.263 | 82.89 +/- 9.6 | 71.33 +/- 8.27 |
| S_N_S | 0.8999 +/- 0.09 | 83.213 | 10.167 | 77.11 +/- 11.1 | 76.52 +/- 9.4 |
| Control 8A029 | 0.9606 +/- 0.16 | 77.523 | 25.513 | | |

This data represents triplicate wells/peptide,
9 images/well
35,000 human endothelial cells/well

This data represents N = 6 to 9
in FGF2-stimulated CAM model

FIG. 4B



7/8




FIG. 5A




FIG. 5B




FIG. 5C



FIG. 5D




FIG. 5E




FIG. 5F

BEST AVAILABLE COPY




FIG. 5G